ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib
The findings emphasize the importance of targeting MEK/ERK signaling in maintaining the long-term benefit of osimertinib through overcoming acquired resistance to osimertinib, warranting further investigation of this therapeutic strategy to improve osimertinib therapeutic efficacy in the clinic.
Gespeichert in:
Veröffentlicht in: | Cancer 2019-12, Vol.126 (6), p.1339-1350 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The findings emphasize the importance of targeting MEK/ERK signaling in maintaining the long-term benefit of osimertinib through overcoming acquired resistance to osimertinib, warranting further investigation of this therapeutic strategy to improve osimertinib therapeutic efficacy in the clinic. |
---|---|
ISSN: | 0008-543X 1097-0142 |
DOI: | 10.1002/cncr.32655 |